The investigation of exercise training in metastatic breast cancer has received minimal attention. This study determined the feasibility and safety of aerobic training in metastatic breast cancer. METHODS: Sixty-five women (age, 21-80 years) with metastatic (stage IV) breast cancer (57% were receiving chemotherapy, and >40% had ! 2 lines of prior therapy) were allocated to an aerobic training group (n 5 33) or a stretching group (n 5 32). Aerobic training consisted of 36 supervised treadmill walking sessions delivered thrice weekly between 55% and 80% of peak oxygen consumption (VO 2peak ) for 12 consecutive weeks. Stretching was matched to aerobic training with respect to location, frequency, duration, and intervention length. The primary endpoint was aerobic training feasibility, which was a priori defined as the lost to follow-up (LTF) rate (<20%) and attendance (!70%). Secondary endpoints were safety, objective outcomes (VO 2peak and functional capacity), and patient-reported outcomes (PROs; quality of life). RESULTS: One of the 33 patients (3%) receiving aerobic training was LTF, whereas the mean attendance rate was 63% 6 30%. The rates of permanent discontinuation and dose modification were 27% and 49%, respectively. Intention-to-treat analyses indicated improvements in PROs, which favored the attention control group (P values > .05). Per protocol analyses indicated that 14 of 33 patients (42%) receiving aerobic training had acceptable tolerability (relative dose intensity ! 70%), and this led to improvements in VO 2peak and functional capacity (P values < .05). CONCLUSIONS: Aerobic training at the dose and schedule tested is safe but not feasible for a significant proportion of patients with metastatic breast cancer. The acceptable feasibility and promising benefit for select patients warrant further evaluation in a dose-finding phase 1/2 study. Cancer 2018;124:2552-60.
INTRODUCTION
Meta-analyses have concluded that exercise training is a safe and feasible intervention associated with significant improvements across a broad array of symptom control outcomes (eg, physical functioning and fatigue) in early-stage breast cancer. 1, 2 The investigation of exercise in advanced or metastatic breast cancer has received minimal attention but may be of significant clinical interest for mitigating treatment and disease-related symptoms (eg, exercise intolerance, quality of life, and fatigue) and potentially improving disease outcomes. An evaluation of exercise treatment in this setting presents a unique challenge because of the disease-and treatment-related sequelae that collectively may alter exercise training tolerability, safety, and response. 3 Thus, initial studies are an essential prerequisite before definitive trials are launched in this population. 4 We conducted a vanguard randomized clinical trial to determine the feasibility and safety of aerobic training in patients with metastatic breast cancer. Secondary objectives were to explore the effects on symptom control outcomes and to identify a subgroup of patients for whom aerobic training was feasible. We hypothesized that aerobic training would be a feasible intervention associated with a significant benefit in comparison with a nonexercise attention control group.
MATERIALS AND METHODS

Study Design, Participants, and Procedures
The full study methods are described in the online supporting information. We conducted a randomized clinical trial among adult women with histologically confirmed metastatic breast cancer, regardless of their menopausal status or concurrent or prior lines of therapy, at Duke University Medical Center (DUMC) and Memorial Sloan Kettering Cancer Center (MSK). Other major eligibility criteria were as follows: 1) an Eastern Cooperative Oncology Group performance status of 0 to 1, 2) approval by the primary attending oncologist for a screening cardiopulmonary exercise test (CPET), 3) the performance of < 150 minutes of moderate-intensity exercise per week, 2 and 4) a review and clearance of an exercise electrocardiogram by a cardiologist. All study procedures were reviewed and approved by the institutional review boards. Participation continued for a maximum of 12 weeks or until unacceptable toxicity, a significant deterioration in the performance status, or a withdrawal of consent (see the online supporting information).
Randomization and Masking
Patients were randomly allocated in a 1:1 ratio to receive aerobic training or attention control (stretching). The random allocation sequence was generated and implemented with REDCap with a random permuted block design. The randomization was stratified according to the prior lines of therapy (<1 vs ! 1) and menopausal status (postmenopausal vs pre/perimenopausal) at study entry. Neither patients nor exercise physiologists were blinded to group allocation.
Study Treatments
Study treatments were matched in terms of setting (clinicbased), monitoring, frequency, duration per session, and length. Dedicated study personnel with bachelor's degrees in exercise science implemented the interventions and individually monitored all sessions in both groups. All sessions were by appointment only, with patients contacted less than 24 hours after an unscheduled missed session. Rescheduling of missed sessions was permitted.
Aerobic training treatment
Aerobic training consisted of 36 supervised treadmill walking sessions delivered thrice weekly for 12 consecutive weeks (see the online supporting information). The intensity of each session alternated between 4 different dose intensities (ie, 55%, 65%, 75%, and 80%) of the maximal metabolic equivalent (MET) (ie, the peak oxygen consumption [VO 2peak ]). The intensity was tailored to each patient on the basis of the workload (ie, treadmill speed/grade) corresponding to a specific percentage of ventilatory thresholds measured during the prerandomization or midpoint (week 6) CPET. The planned dose and scheduling of exercise treatment were continually altered and progressed in conjunction with Figure 1 . Planned aerobic training dose intensity and schedule: schematic of the planned aerobic training prescription template implemented for all patients allocated to the aerobic training group. The intensity and duration of each individual session (ie, dose) as well as the schedule of treatment doses across the study intervention period are presented. The intensity of each session was conducted at 1 of 4 different doses, which are depicted by the colored bars as percentages of VO 2peak : 1) black for 55%, 2) blue for 65%, 3) orange for 70% to 75%, and 4) gray for 80% to 85%. All doses were individualized to each patient on the basis of the baseline CPET. Black dots depict the planned duration of each session, which ranged from a minimum of 20 minutes per session to a maximum of 45 minutes per session. At the end of week 6, the CPET was repeated to represcribe the exercise intensity (green bar). The prescription template depicts the planned intensity, duration, and scheduling of sessions as per protocol under the assumption that no sessions were missed. CPET indicates cardiopulmonary exercise test; VO 2peak , peak oxygen consumption.
appropriate rest/recovery sessions across the entire intervention period (ie, nonlinear periodized prescription; Fig. 1 ), and they were standardized across all patients. This prescription approach was selected on the basis of a prior randomized clinical trial among patients receiving neoadjuvant chemotherapy for operable breast cancer. 5 The safety and verification of the training intensity of each session were evaluated with a combination of the heart rate (continuous), blood pressure (every 10 minutes), and rate of perceived exertion (every 15 minutes). Dose modification of any session was permitted and performed by the exercise physiologist monitoring each session according to standardized criteria (Supporting Table 1 ).
Attention control
Attention control consisted of 3 individualized stretching sessions per week with 12 to 20 different positions; it followed a standardized progressive approach for 10 to 30 seconds per stretch for a total of 20 to 45 minutes per session. 6 
Outcomes
The primary endpoint was feasibility as evaluated by the composite endpoint of the lost to follow-up (LTF) rate (the completion of postintervention assessments) and attendance (the ratio of total attended treatments to planned treatments). Other secondary feasibility endpoints were permanent discontinuation (treatment discontinuation before week 12), treatment interruption (missing ! 3 consecutive sessions), dose modification (!10% of sessions requiring modification [reduction/ escalation] of the intensity or duration), pretreatment dose modification (reduction of the pretreatment session intensity), early session termination (termination of the session before the planned duration), and adherence (compliance with the planned dose per session). Planned and completed exercise doses in all sessions were quantified as METs per session, with the relative dose intensity (RDI) defined as the ratio of the total completed cumulative dose to the total planned cumulative dose (see the online supporting information). 7 Secondary endpoints were safety, VO 2peak , functional capacity, and patientreported outcomes (PROs). Safety was evaluated by the type and prevalence of serious (eg, important medical events) and nonserious adverse events (eg, knee and back pain) during aerobic training sessions. The hematological profile was evaluated via complete blood counts. Cardiorespiratory fitness (VO 2peak ) was assessed with a symptom-limited CPET on an electronic motorized treadmill test with 12-lead electrocardiogram monitoring (Mac 5000; GE Healthcare) according to standard procedures. 8 All CPETs were conducted at a dedicated research laboratory at both institutions. Functional capacity was assessed with the 6-minute walk test, 9 the 30-second chair-stand test, 10 and the timed up and go test.
11 PROs included quality of life (Functional Assessment of Cancer Therapy-Breast), 12 physical functioning (36-Item Short Form Health Survey), 13 fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue), 14 sleep quality (Pittsburgh Sleep Inventory), 15 and pain (Brief Pain Inventory). 16 Nonprotocol exercise was assessed with a validated survey. 17 Dedicated study personnel with degrees in exercise science conducted all baseline and postintervention physiological evaluations. All outcomes were evaluated at prerandomization (study treatments were initiated at 14 days) and were repeated within 7 days of the final treatment session at postintervention (month 3).
Statistical Analysis
Feasibility was evaluated according to protocol-specified criteria for the intention-to-treat population: 1) an LTF rate < 20% and 2) a mean attendance rate ! 70%. Standard definitions of feasibility with exercise training are not available for any clinical population, so the criteria selected here are based on LTF and attendance rates reported in prior exercise training studies in the oncology setting. 18, 19 The allocation of 36 patients to the aerobic training group provided 80% power to differentiate between 60% and 80% feasibility rates with a 1-tailed, 1-sample binomial test with a .05 level of significance. A protocol-specified stopping rule was a serious adverse event rate of !2 per 9 patients, ! 3 per 18 patients, or ! 4 per 36 patients in the aerobic training group.
The baseline medical and demographic characteristics of each group are summarized with descriptive statistics (means and standard deviations or frequencies and percentages) and compared with the Wilcoxon rank-sum test or Fisher's exact test, as appropriate. The aerobic training dose, feasibility, and safety are reported with descriptive statistics. We also explored differences in feasibility endpoints as a function of study site (DUMC and MSK). Wilcoxon signed-rank tests were used to test for within-group and between-group changes in symptom control endpoints from the baseline to the postintervention. An analysis of covariance was used to estimate the difference in endpoints at postintervention between groups after adjustments for baseline values and study site. All analyses used the baseline carried forward imputation technique for LTF patients. Wilcoxon signed-rank tests were applied to test for differences in study endpoints by tolerability (acceptable tolerability: RDI ! 70%) and to determine whether an RDI ! 70% was associated with a superior benefit versus an RDI < 70%. A 2-sided significance level of .05 was used for all statistical tests. All statistical analyses were conducted with SAS 9.4 (SAS Institute, Cary, North Carolina).
RESULTS
A total of 65 patients were allocated to the aerobic training group (n 5 33) or the attention control group (n 5 32; (Table 1 ). There were no between-group differences in changes in nonprotocol exercise exposure during the intervention (P 5 .44).
For the primary endpoint, 1 of 33 patients (3%) receiving aerobic training was LTF, whereas the mean attendance rate was 63% 6 30% (range, 0%-100%; 744 of 1188 planned sessions). The most common reasons for missed sessions were health-related (eg, disease progression and pain) and non-health-related (eg, motivation and vacation; Supporting Table 2 ). For secondary feasibility endpoints, the mean cumulative planned and completed aerobic training doses were 81.2 6 22.6 MET-hours (range, 45.9-175.9 MET-hours) and 45.7 6 24.7 METhours (range, 0.0-87.3 MET-hours; Fig. 3A,B) ; this equated to a mean RDI of 61% 6 30%. Aerobic training was permanently discontinued in 9 of 33 patients (27%; Supporting Table 3 ). The reasons for discontinuation were disease progression (n 5 3 [9%]), pain (n 5 2 [6%]), and non-health-related (motivational) reasons (n 5 4 [12%]). The dose interruption rate was 46% (15 of 33 patients), with the most common reasons for interruption being time constraints (n 5 4 [12%]) and vacation (n 5 3 [9%]). The dose modification rate was 49% (16 of 33 patients); a total of 88 of 744 attended sessions (12%) required a dose reduction. A total of 12 patients (36%) required at least 1 session to be terminated early because of a nonserious health-related event. On the basis of study site, there were significant differences in attendance, dose modification, and pretreatment dose modification, with all being inferior at DUMC in comparison with MSK (Supporting Table  4 ). DUMC patients were more likely to have more than 3 lines of prior treatment and a lower VO 2peak at study entry (Supporting Table 5 ). Two patients were transitioned from treadmill walking to stationary cycle ergometry because of preexisting orthopedic comorbidities.
Four of 69 consenting patients (6%) were deemed ineligible because they had electrocardiogram abnormalities No serious adverse events were observed during aerobic training. A total of 24 of 33 patients (73%) receiving aerobic training experienced at least 1 nonserious adverse event during aerobic training; a total of 76 independent nonserious events in 744 attended sessions (10%) were observed. The most common events were an abnormal heart rate, pain in extremity, and fatigue (Table 2) . No aerobic training-associated adverse events led to permanent discontinuation. There were no differences in hematological profile between patients receiving aerobic training and patients receiving attention control (Supporting Table 6 ). A total of 7 nonserious adverse events were observed in the attention control group.
For intention-to-treat analyses, VO 2peak and PROs were generally maintained in both groups (P values > .05; Supporting Table 7 ). The only between-group differences were changes in Functional Assessment of Cancer Therapy-General (P 5 .03) and Functional Assessment of Cancer Therapy-Social Well-Being (P 5 .04), with the attention control group being favored. All functional capacity endpoints significantly improved in both groups, with no significant differences between groups (P values > .05; Supporting Table 8 ). Per protocol analyses indicated that aerobic training was feasible (RDI ! 70%) in 14 of 33 patients (42%). These patients had higher VO 2peak values and had received fewer than 3 lines of prior treatment at study entry in comparison with patients with an RDI < 70% (Supporting Table 9 ). Aerobic training feasibility on the basis of RDI is presented in Supporting Table 10 . An RDI ! 70% was associated with significant improvements in functional capacity and cardiorespiratory fitness endpoints but, in general, not PROs (Supporting Table 10 ). 
DISCUSSION
On the basis of protocol-defined criteria, supervised aerobic training at the dose and schedule tested is safe but not feasible for a significant subset of pretreated patients receiving concurrent cytotoxic treatment for metastatic breast cancer. Few prior exercise studies have been designed with this prespecified objective of feasibility and safety; they have rather focused on symptom control efficacy endpoints or the feasibility of patient recruitment. Furthermore, the evaluation of exercise feasibility is limited to monitoring and reporting of adherence, which is typically limited to LTF and attendance rates. 7 In this context, the findings of this study are consistent with the only other randomized trial of exercise in metastatic breast cancer. The Metastatic Exercise Training Trial (METT) study evaluated the tolerability and efficacy of a 16-week exercise program in 101 patients receiving any prior line and any therapy for metastatic breast cancer (42% were receiving concurrent chemotherapy at study entry). 20 Participation in regular exercise was not a study exclusion criterion (patients allocated to the exercise and control groups were moderately active at study entry). The exercise program consisted of a predominantly home-based prescription with the objective of achieving 150 minutes of moderate-intensity exercise per week. Details of the exercise prescription characteristics with respect to frequency, duration, and modality as well as how exercise was tailored to each patient were not provided. Over the 16-week study period, intervention participants increased exercise exposure by a mean of 62.4 6 102.8 min/wk. The overall LTF rate was 22%, with patients assigned to exercise more likely to be LTF. The attendance rate was not reported. 20 The findings of the current study are also not too dissimilar from those of randomized trials of supervised exercise training in patients receiving adjuvant chemotherapy for early-stage breast cancer. For example, in the Supervised Trial of Aerobic Versus Resistance Training (START) study, the LTF rate was 8%, with attendance rates of 72% and 68% in the aerobic training and Figure 3 . Ratio of the planned aerobic training dose to the completed aerobic training dose: (A) mean METs per week, (B) mean total cumulative dose, and (C) individual patient RDI. Data are presented for the intention-to-treat population. The planned dose is depicted as blue bars, with the completed dose depicted as red bars. The average METs were assigned to sessions in which the intensity was reduced (eg, 75% reduced to 65% and imputed as 70%), whereas missed sessions were assigned 0 METs. MET indicates metabolic equivalent; RDI, relative dose intensity.
resistance training groups, respectively. 21 In the Physical exercise during Adjuvant Chemotherapy Effectiveness Study (PACES) study, the LTF rate was 11%, with an attendance rate of 71% for patients receiving supervised aerobic and resistance exercise training. 22 On the basis of the predefined tolerability thresholds applied in the current study, exercise training would be considered of acceptable feasibility in the START and PACES studies. However, whether such thresholds are appropriate or should be different in the adjuvant setting versus the metastatic setting is not clear because standardized definitions of feasibility and safety with exercise training are not available for any clinical population.
Metrics adapted from pharmacological trials indicated that despite an LTF rate of only 1%, approximately one-third of the patients permanently discontinued aerobic training; this rate was comparable to that observed in the METT study, 20 the only other study to report an exercise discontinuation rate in the oncology setting. Similarly, the dose modification and early session termination rates in the current study were 33% and 36%, respectively, yet the attendance rate for these sessions would be reported as 100%. Thus, the use of standard exercise metrics such as LTF and attendance rates provides limited insight and could lead to erroneous conclusions regarding the actual feasibility or tolerability of exercise treatment for a given indication. To this end, our findings indicate that further analysis of feasibility and potentially efficacy as a function of site in multisite trials is also likely to be important. Although it was not feasible for a significant subset of patients, the lack of serious adverse events indicates that aerobic training has an acceptable safety profile. Nevertheless, several nonserious events were observed that triggered dose modification and, more importantly, early session termination, and this highlights the importance of close monitoring and supervision of exercise training interventions, at least in select patients, together with formalized monitoring and reporting of tolerability and safety.
In both pharmacological and nonpharmacological trials, several different terms, including feasibility, tolerability, and adherence, are used to describe the implementation or completion of study treatment. In oncology drug trials, the most commonly used term is tolerability, which appears appropriate because noncompliance with the planned treatment schedule is mostly due to treatmentrelated dose-limiting toxicities. In contrast, however, noncompliance in exercise trials may be due to both healthrelated and non-health-related (eg, motivational) reasons. Thus, the term feasibility may be more appropriate for reporting exercise treatment trials because this is a more all-encompassing term capturing the many unique elements for characterizing exercise treatment implementation/completion in a given clinical population and setting. The use of terminology is arguably a matter of investigator preference; the most important recommendation for future trials is that, regardless of which term or terms are selected, all are clearly defined and operationalized to facilitate data interpretation and cross-trial comparisons.
Contrary to our hypotheses, aerobic training, in general, was not associated with improvements in cardiorespiratory fitness or PROs for the intention-to-treat population; these findings, however, are not unexpected in context of the high permanent discontinuation rate and moderate attendance rate. The lack of an exercise benefit for both objective outcomes and PROs observed in the current study is consistent with that reported for patients with metastatic (advanced) cancer. 19, 20 Specifically, in this study, VO 2peak and PROs were generally maintained in both the aerobic training and attention control groups over the 12-week study period, although attention control was associated with superior improvements in quality-oflife endpoints in comparison with aerobic training. A closer inspection of the data indicates that these differences do not reflect a detrimental effect of aerobic training but rather reflect the beneficial impact of the attention control stretching intervention. All prior randomized studies investigating the feasibility and efficacy of exercise in patients with metastatic cancer as well as the majority of studies in the adjuvant setting have compared the efficacy of exercise with nonintervention control groups, 18 which do not receive the same level of attention or social interaction as those allocated to exercise groups. It is, therefore, unclear whether the observed significant benefit of exercise for PROs reflects the actual psychosocial benefit of exercise or the social interaction aspects related to participation in an exercise intervention. Our data suggest that nonexercise interventions that match the degree of social interaction typically experienced in exercise groups are equally as efficacious if not more efficacious at improving certain PROs, particularly social aspects of quality of life; on the other hand, exercise appears to be a more efficacious intervention for physical/functional aspects of quality of life. In per protocol analyses, patients who had higher baseline VO 2peak values and received fewer than 3 lines of prior therapy were able to tolerate aerobic training (RDI ! 70%) and derived a significant physiological benefit. The significant, approximately 11% VO 2peak decline in patients with unacceptable feasibility of aerobic training (RDI < 70%) is comparable to that observed in the adjuvant setting, 5, 21, 22 although ours is the first to report such a decline in patients with metastatic breast cancer. Again, similarly to the adjuvant setting, 5, 21, 22 if feasible, aerobic training completely abrogates this decline. This may be of clinical importance because VO 2peak and functional capacity measures 23 are significant independent predictors of survival in numerous clinical populations, including patients with metastatic breast cancer. 24 Moreover, because of the incurable nature of metastatic disease, treatment-related morbidity and PROs are of major clinical relevance. 25 Collectively, our findings establish the platform for initiating phase 1/2 dose-finding studies in metastatic breast cancer patients with a good performance status receiving either first-or second-line therapy to determine the efficacy of exercise for both mitigating treatment-related toxicities and improving PROs.
The strengths of this trial include the rigorous conduct adhering to the principles of exercise training, 26 the adherence to reporting standards from the Consolidated Standards of Reporting Trials guidelines for nonpharmacological trials 27 and Template for Intervention Description and Replication statements, 28 the novel adoption of pharmacological metrics for rigorously evaluating exercise training tolerability and safety, the dual-site design, the gold-standard measurement of efficacy endpoints, and the use of an attention control comparison group as opposed to a nonintervention or wait-list control group. 18 Limitations include the heterogeneous study cohort, the short intervention period, the lack of generalizability to patients unable to attend supervised sessions (eg, those who have a poor performance status or are experiencing significant dose-limiting toxicities), and the lack of clinical outcome data.
In conclusion, on the basis of predefined criteria, supervised aerobic training at the dose and schedule tested is safe but not feasible among pretreated patients with metastatic breast cancer receiving concurrent therapy. The acceptable tolerability and promising benefit of aerobic training in a significant subset of patients warrant further evaluation in a phase 1/2 study.
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